Přejít k obsahu
Merck
  • Risedronate transdermal delivery system based on a fumaric copolymer for therapy of osteoporosis.

Risedronate transdermal delivery system based on a fumaric copolymer for therapy of osteoporosis.

Materials science & engineering. C, Materials for biological applications (2017-05-10)
Magalí Pasqualone, Héctor A Andreetta, M Susana Cortizo
ANOTACE

Transdermal drug delivery system (TDDS) could be seen as alternative to the oral administration which avoids several adverse effects. In this study a novel TDDS for risedronate (RI), a bisphosphonate used for osteoporosis treatment, based on a vinyl acetate-dioctylfumarate copolymer, poly(VA-co-DOF), previously synthetized, was developed. Two membranes including 6 and 12% (w/w) of drug were obtained, which exhibited good transparence and homogeneous drug distribution, as evaluated by optical microscopy. FTIR spectroscopy and differential scanning calorimetry (DSC) analysis showed no significant drug/polymer interactions, only a plasticizer effect. A new reverse phase high-performance liquid chromatography (RP-HPLC) method for quantification of RI was development and validated, which demonstrate good linearity, reproducibility and accuracy with limits of detection (LOD) and quantification (LOQ) of 0.38μg/mL and 1.17μg/mL, respectively. High drug load efficiency and great drug stability were found. The analysis of the drug release kinetics, fitting to Ritger-Peppas model, leads to values of the diffusion coefficient (n) of 1.37 and 1.05, for 6 and 12% (w/w) RI, respectively. These results correspond to super case transport II and suggest a complex transport mechanism, regulated by the mobility of the polymer chains. Together, these results indicate that this new TDDS could be useful for osteoporosis treatment without adverse effect.

MATERIÁLY
Číslo produktu
Značka
Popis produktu

Sigma-Aldrich
3-Pyridylacetonitrile, 98%